just saw that DiaMedica brought on Julie Krop as their new CMO and honestly her background is pretty solid. she spent over 20 years in biopharma, was actually CMO at PureTech Health before this and ran a bunch of rare disease programs through Phase 2. so Julie Krop coming in to lead their DM199 development makes sense given what they're trying to do with preeclampsia treatment.

the interesting part is Julie Krop apparently has direct experience with preeclampsia drug development already, which is exactly what DiaMedica is focused on. they're pushing toward late-stage trials so having someone who's already navigated that space before could be a real asset. replacing Lorianne Masuoka who stepped down for personal reasons.

their CEO Rick Pauls basically said they're betting on her track record of getting drugs from concept to approval. whether that actually translates to success here remains to be seen but at least they're not just hiring random people for these roles. you don't get 20+ years in this industry without knowing how to move things forward.